ArticleJHEP reports : innovation in hepatology2026
Higher prevalence of cytomegalovirus and Epstein-Barr virus in acute-on-chronic liver failure.
Article in JHEP reports : innovation in hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04975490 (Beobachtungsstudie für Die Charakterisierung Der Pathogenese Des Akut-auf-chronischen Leberversagens), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Beobachtungsstudie für Die Charakterisierung Der Pathogenese Des Akut-auf-chronischen Leberversagens
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsAcute-on-chronic liver failure (ACLF) is a life-threatening syndrome characterized by rapid deterioration of organ function in pre-existing chronic liver disease. Patients who develop ACLF within 90 days after decompensation are referred to as pre-ACLF. Known precipitants include bacterial infections and viral hepatitis. However, in 40-60% of patients, the precipitant remains unknown. Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) are highly prevalent viruses, but their impact on ACLF is unclear.
methods211 patients (43 ACLF, 16 pre-ACLF, and 152 non-ACLF) of the ACLF-I study and an external validation cohort with 153 patients (39 ACLF, 33 pre-ACLF, and 81 non-ACLF) were included. Sera were analyzed for CMV/EBV DNA (multiplex qPCR), cytokines in 102 ACLF-I samples (multiplex assays), and immunoglobulins in 80 case-control matched ACLF-I and 20 validation cohort patients (immunoassays), and correlated with clinical data.
resultsIn the ACLF-I group, a higher prevalence of CMV DNAemia (8.9% vs. 25.6%, odds ratio [OR] 3.51, 95% CI 1.47-8.34, p <0.01) and EBV DNAemia (6.6% vs. 16.3%, OR 3.01, 95% CI 1.10-8.62, p <0.05) was observed in ACLF compared to non-ACLF cases, despite the absence of clinical signs of viral infections. 54.8% of DNAemic ACLF patients in the validation cohort had no identified precipitant compared to 26.5% in ACLF patients without DNAemia (p <0.05). CMV was associated with liver failure (p <0.001) and with 90-day mortality (p <0.001) in the regression model. DNAemia was associated with a distinct pattern of inflammatory activity. The results were validated externally. Serological analyses revealed that reactivation rather than primary infection occurred in most cases defined as DNAemic.
conclusionsPresence of CMV/EBV DNAemia in chronic liver disease may contribute to the development of ACLF by exacerbating liver inflammation and impairing hepatocellular function. IMPACT AND IMPLICATIONS: Despite ACLF being a life-threatening syndrome, the underlying precipitant cannot be identified in 30-40% of cases. As a result, intervention in ACLF development is limited to cases with known precipitants. To our knowledge, this is the first time it is shown that previously undiagnosed CMV and EBV DNAemia might act as a precipitating event inducing ACLF. We propose that routine screening and proper treatment for CMV and EBV in decompensated cirrhotic patients can intervene in ACLF development. This hypothesis needs to be assessed in prospective studies. CLINICAL TRIALS REGISTRATION: NCT04975490.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.